Stock Events

Stock Events

Prescient Therapeutics Limited 

€0.032000
0
+€0.00+1.59% Friday 06:02

Statistics

Day High
0.032
Day Low
0.032
52W High
0.0605
52W Low
0.0265
Volume
-
Avg. Volume
-
Mkt Cap
33.65M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

21AugExpected
Q3 2017
Q2 2021
Q2 2026
-0.01
-0.01
-0.01
-0
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-4.09MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow UDD.F. It's not an investment recommendation.
Insurance Australia Group Limited
2
IAG.AU
Imugene
2
IMU.AU
Immutep Limited
2
IMM.AU

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. has a broad portfolio in oncology and cell therapy, making it a major competitor in the cancer treatment market.
Novartis
NVS
Mkt Cap292.35B
Novartis AG has a strong presence in the oncology market, including CAR-T cell therapies, making it a key competitor in cancer treatment innovations.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. has a diverse oncology portfolio, including biologics and small molecules, competing across several areas of cancer treatment.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a leader in oncology with its blockbuster drug Keytruda, competing in the broader oncology pharmaceuticals market.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has a comprehensive oncology portfolio, including cellular therapies and immunotherapies, making it a direct competitor in cancer treatment.

About

Prescient Therapeutics Limited (PTX.AX) is an Australian clinical-stage oncology firm dedicated to creating novel therapeutic agents for various cancer types. The company's primary experimental compound, PTX-200, is currently undergoing several clinical trials: Phase 2a for HER2-negative breast cancer, Phase 1B/2 for acute myeloid leukemia that has relapsed or is resistant to treatment, and Phase 1b for ovarian cancer that is recurrent, persistent, or resistant to platinum-based therapies. Additionally, PTX-100, a RhoA inhibitor, is being developed to target both blood cancers and solid tumors, specifically those characterized by Ras and RhoA genetic mutations. Prescient Therapeutics has also forged a strategic alliance with The University of Texas MD Anderson Cancer Center to advance the development of a blood cancer binder for their OmniCAR platform. Founded in Melbourne, Australia, in 1986, the company operated as Virax Holdings Limited until its rebranding as Prescient Therapeutics Limited in December 2014.
Show more...
CEO
James McDonnell
Employees
3
Country
Australia
ISIN
AU000000PTX3
WKN
000A12GQZ

Listings

F
DE
UDD.F
AU
AU
PTX.AU

0 Comments

Share your thoughts

FAQ

What is Prescient Therapeutics Limited stock price today?▼
The current price of UDD.F is €0.03 EUR — it has increased by +1.59% in the past 24 hours. Watch Prescient Therapeutics Limited stock price performance more closely on the chart.
What is Prescient Therapeutics Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Prescient Therapeutics Limited stocks are traded under the ticker UDD.F.
What is Prescient Therapeutics Limited market cap?▼
Today Prescient Therapeutics Limited has the market capitalization of 33.65M
When is the next Prescient Therapeutics Limited earnings date?▼
Prescient Therapeutics Limited is going to release the next earnings report on February 19, 2027.
What is Prescient Therapeutics Limited revenue for the last year?▼
Prescient Therapeutics Limited revenue for the last year amounts to 0 EUR.
What is Prescient Therapeutics Limited net income for the last year?▼
UDD.F net income for the last year is -4.09M EUR.
How many employees does Prescient Therapeutics Limited have?▼
As of September 05, 2026, the company has 3 employees.
In which sector is Prescient Therapeutics Limited located?▼
Prescient Therapeutics Limited operates in the Health & Wellness sector.
When did Prescient Therapeutics Limited complete a stock split?▼
The last stock split for Prescient Therapeutics Limited was on December 02, 2014 with a ratio of 1:20.
Where is Prescient Therapeutics Limited headquartered?▼
Prescient Therapeutics Limited is headquartered in Melbourne, Australia.